NCT06589700 B2AD-Risk AFDAS Evolution of Burden of AF
| NCT ID | NCT06589700 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Luciano A. Sposato |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-10-16 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-10-16 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Each year, 7.8 million people worldwide experience an ischemic stroke, often caused by atrial fibrillation (AF). AF is a major contributor to severe, disabling, and deadly strokes. About 20% to 30% of ischemic stroke patients have AF before their stroke. Of the remaining 70% to 80% without known arrhythmias, up to 24% are newly diagnosed with AF after intensive cardiac monitoring, totaling 1.3 to 1.5 million new AF cases detected after stroke globally each year. Oral anticoagulants (OACs) can reduce stroke risk related to AF by 64% and lead to milder strokes with lower disability and mortality. Neurologists use cardiac monitoring to detect AF in stroke patients. This study focuses on patients who have had an ischemic stroke and are newly diagnosed with AF. The goal is to understand how AF progresses over time. The investigators will track changes in AF severity and frequency, monitor biomarkers related to heart health, assess the size and function of the left atrium, and observe new risk factors like hypertension. Patients will be grouped based on their AF diagnosis method: ECG, a portable device recording heart activity for less than 7 days, or one recording for 7 to 30 days. The investigators hypothesize that AF burden will increase, new risk factors will emerge, biomarkers will rise, and the left atrium will worsen over time. Participants will be followed for up to 24 months with regular assessments. The study aims to provide insights into AF progression in stroke patients, potentially improving treatments and prevention strategies.
Eligibility Criteria
Inclusion Criteria: * Adult patients with cortical or subcortical, cryptogenic or non-cryptogenic acute ischemic stroke * Any of the following types of AF: * Paroxysmal AF known before stroke onset (KAF). * Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS) * Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS) Exclusion Criteria: * Patients not willing to consent * Permanent or persistent AF * Allergy to iodinated contrast agents
Contact & Investigator
Luciano A Sposato, MD
PRINCIPAL INVESTIGATOR
Western University
Frequently Asked Questions
Who can join the NCT06589700 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06589700 currently recruiting?
Yes, NCT06589700 is actively recruiting participants. Contact the research team at diana.ayan@lhsc.on.ca for enrollment information.
Where is the NCT06589700 trial being conducted?
This trial is being conducted at London, Canada.
Who is sponsoring the NCT06589700 clinical trial?
NCT06589700 is sponsored by Luciano A. Sposato. The principal investigator is Luciano A Sposato, MD at Western University. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.